Compare · DVA vs FMS
DVA vs FMS
Side-by-side comparison of DaVita Inc. (DVA) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.03B, about the same size as DVA ($11.53B).
- Over the past year, DVA is up 51.0% and FMS is down 18.1% - DVA leads by 69.2 points.
- FMS has been more active in the news (5 items in the past 4 weeks vs 3 for DVA).
- FMS has more recent analyst coverage (24 ratings vs 14 for DVA).
- Company
- DaVita Inc.
- Fresenius Medical Care AG
- Price
- $189.13+4.65%
- $22.12+2.67%
- Market cap
- $11.53B
- $12.03B
- 1M return
- -2.51%
- -3.70%
- 1Y return
- +51.02%
- -18.15%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 14
- 24
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest DVA
- DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
- DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
- Chief Operating Officer, DKC Maughan David Paul covered exercise/tax liability with 7,501 shares, decreasing direct ownership by 8% to 86,604 units (SEC Form 4) to cover withholding tax
- Alebund Pharmaceuticals Announces 2026 Interim Results
- DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
- Director Hollar Jason M. was granted 278 shares, increasing direct ownership by 4% to 6,883 units (SEC Form 4)
- Director Desoer Barbara J was granted 278 shares (SEC Form 4)
- Director Pullin Dennis W was granted 278 shares, increasing direct ownership by 10% to 2,949 units (SEC Form 4)
- Director Moore Gregory J. was granted 278 shares, increasing direct ownership by 4% to 8,091 units (SEC Form 4)
- Director Yale Phyllis R was granted 278 shares, increasing direct ownership by 3% to 9,803 units (SEC Form 4)
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
- Fresenius Medical downgraded by Berenberg
- Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG